PMID- 32791177 OWN - NLM STAT- MEDLINE DCOM- 20210106 LR - 20210106 IS - 1096-0333 (Electronic) IS - 0041-008X (Linking) VI - 404 DP - 2020 Oct 1 TI - Epigenetic repression of AT2 receptor is involved in beta cell dysfunction and glucose intolerance of adult female offspring rats exposed to dexamethasone prenatally. PG - 115187 LID - S0041-008X(20)30313-6 [pii] LID - 10.1016/j.taap.2020.115187 [doi] AB - Prenatal exposure to dexamethasone (PDE) impairs pancreatic beta cell development and glucose homeostasis in offspring especially females. To explore the underlying intrauterine programming mechanism, pregnant Wistar rats were subcutaneously administered with dexamethasone (0, 0.2 and 0.8 mg/kg.d) from gestational days (GD) 9 to 20. Female offspring were collected on GD20 (fetus) and in postnatal week 28 (adult), respectively. PDE reduced the serum insulin levels, beta cell mass, and pancreatic insulin expressions in fetuses and adults, causing glucose intolerance after maturity. The persistent suppression of pancreatic angiotensin II receptor type 2 (AT2R) expression before and after birth could be observed in the PDE females, which is accompanied with decreased histone 3 lysine 14 acetylation (H3K14ac) and H3K27ac levels in AT2R promoter. PDE increased the gene expressions of glucocorticoid receptor (GR) and histone deacetylase 2 (HDAC2) in fetal pancreas. Furthermore, dexamethasone inhibited insulin biosynthesis while activated GR and HDAC2 expression in the rat INS-1 cells. The AT2R expression was repressed by dexamethasone in vitro but only H3K27ac levels in AT2R promoter were lowered. Dexamethasone enhanced the interaction between GR and HDAC2 proteins as well as the binding of GR/HDAC2 complex to AT2R promoter. Moreover, overexpression of AT2R could restore the suppressed insulin biosynthesis induced by dexamethasone in vitro, and both GR antagonist and histone deacetylase abolished the decreased H3K27ac level and gene expression of AT2R. In conclusion, continuous epigenetic repression of AT2R before and after birth may be involved in beta cell dysfunction and glucose intolerance of the PDE adult female offspring. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Kou, Hao AU - Kou H AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China; Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 40071, China; Hubei Provincial Key Laboratory of Developmentally Originated Diseases, Wuhan 430071, China. FAU - Gui, Shuxia AU - Gui S AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China. FAU - Dai, Yongguo AU - Dai Y AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China. FAU - Guo, Yu AU - Guo Y AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Diseases, Wuhan 430071, China. Electronic address: guoy@whu.edu.cn. FAU - Wang, Hui AU - Wang H AD - Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Diseases, Wuhan 430071, China. Electronic address: wanghui19@whu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200811 PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Glucocorticoids) RN - 0 (Receptor, Angiotensin, Type 2) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Animals MH - Dexamethasone/*toxicity MH - Epigenesis, Genetic MH - Female MH - Gene Expression Regulation/drug effects MH - Glucocorticoids/toxicity MH - *Glucose Intolerance MH - Insulin-Secreting Cells/*metabolism MH - Pregnancy MH - *Prenatal Exposure Delayed Effects MH - Rats MH - Receptor, Angiotensin, Type 2/genetics/*metabolism OTO - NOTNLM OT - Angiotensin Receptor II OT - Dexamethasone OT - Glucose Intolerance OT - Histone Acetylation OT - Pancreatic beta Cell COIS- Declaration of Competing Interest All authors declare they have no conflict of interest. EDAT- 2020/08/14 06:00 MHDA- 2021/01/07 06:00 CRDT- 2020/08/14 06:00 PHST- 2020/05/17 00:00 [received] PHST- 2020/07/22 00:00 [revised] PHST- 2020/08/07 00:00 [accepted] PHST- 2020/08/14 06:00 [pubmed] PHST- 2021/01/07 06:00 [medline] PHST- 2020/08/14 06:00 [entrez] AID - S0041-008X(20)30313-6 [pii] AID - 10.1016/j.taap.2020.115187 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2020 Oct 1;404:115187. doi: 10.1016/j.taap.2020.115187. Epub 2020 Aug 11.